<i>SOX9</i> is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition.
de Bono, J
MetadataShow full item record
Aggressive lethal prostate cancer is characterised by tumour invasion, metastasis and androgen resistance. Understanding the mechanisms by which localised disease progresses to advanced lethal stages is key to the development of effective therapies. Here we have identified a novel role for the transcription factor, SOX9, as a driver of aggressive invasive prostate cancer. Using genetically modified mouse models, we show that increased <i>Sox9</i> expression in the prostate epithelia of animals with <i>Pten</i> loss leads to a highly invasive phenotype and metastasis. In depth analysis of these mice and related <i>in vitro</i> models reveals that SOX9 acts a key regulator of various processes that together promote tumour progression. We show that this factor promotes cell lineage plasticity with cells acquiring properties of basal stem cells and an increase in proliferation. In addition, increased SOX9 leads to changes in cytoskeleton and adhesion, deposition of extracellular matrix and epithelia to mesenchyme transition, properties of highly invasive cells. Analysis of castrated mice showed that the invasive phenotype driven by SOX9 is independent of androgen levels. Our study has identified a novel driver of prostate cancer progression and highlighted the cellular and molecular processes that are regulated by <i>Sox9</i> to achieve invasive disease.
Version of record
Prostate Cancer Targeted Therapy Group
Development & Cancer
License start date
Oncotarget, 2018, 9 (7), pp. 7604 - 7615